published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 14-days deathsdetailed resultsSekine (PLACOVID), 2021 2.14 [0.70; 6.58] 2.14[0.70; 6.58]Sekine (PLACOVID), 202110%160NAnot evaluable death D28detailed resultsAbuhasira, 2021 0.72 [0.23; 2.24] AlQahtani, 2020 0.47 [0.04; 5.69] COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47] CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80] Jamaati, 2021 1.19 [0.38; 3.72] Li, 2020 0.59 [0.22; 1.59] Pouladzadeh, 2021 0.31 [0.01; 10.20] Raman, 2021 0.49 [0.02; 15.10] RECOVER, 2021 1.09 [0.38; 3.13] Sekine (PLACOVID), 2021 1.38 [0.73; 2.62] Shu, 2020 0.38 [0.02; 8.14] Tabarsi, 2020 1.10 [0.45; 2.67] Talaschian, 2021 1.56 [0.34; 7.13] Veiga, 2021 2.70 [0.92; 7.92] 1.07[0.86; 1.34]Abuhasira, 2021, AlQahtani, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, Jamaati, 2021, Li, 2020, Pouladzadeh, 2021, Raman, 2021, RECOVER, 2021, Sekine (PLACOVID), 2021, Shu, 2020, Tabarsi, 2020, Talaschian, 2021, Veiga, 2021140%1,444moderatelow deathsdetailed resultsAlQahtani, 2020 0.47 [0.04; 5.69] Cao, 2020 0.71 [0.36; 1.40] CAPSID, 2021 0.84 [0.28; 2.50] COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47] CODEX (Tomazini), 2020 0.97 [0.72; 1.31] CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71] CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80] CP-COVID-19, 2021 3.20 [0.62; 16.39] Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25] Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92] DEXA-COVID19, 2020 2.00 [0.21; 18.87] Jamaati, 2021 1.19 [0.38; 3.72] Li, 2020 0.59 [0.22; 1.59] Pouladzadeh, 2021 0.31 [0.01; 10.20] Rahmani, 2020 0.29 [0.05; 1.56] Raman, 2021 0.49 [0.02; 15.10] Rasheed, 2020 0.13 [0.01; 1.09] RECOVER, 2021 1.09 [0.38; 3.13] REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93] REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15] REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95] Sekine (PLACOVID), 2021 1.38 [0.73; 2.62] Shu, 2020 0.38 [0.02; 8.14] Steroids-SARI, 2020 0.91 [0.29; 2.86] Tabarsi, 2020 1.10 [0.45; 2.67] Talaschian, 2021 1.25 [0.30; 5.14] Veiga, 2021 2.70 [0.92; 7.92] 0.88[0.79; 0.99]AlQahtani, 2020, Cao, 2020, CAPSID, 2021, COALITION II Covid-19 Brazil (Furtado), 2020, CODEX (Tomazini), 2020, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, DEXA-COVID19, 2020, Jamaati, 2021, Li, 2020, Pouladzadeh, 2021, Rahmani, 2020, Raman, 2021, Rasheed, 2020, RECOVER, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (plasma), 2021, REMAP-CAP (tocilizumab), 2021, Sekine (PLACOVID), 2021, Shu, 2020, Steroids-SARI, 2020, Tabarsi, 2020, Talaschian, 2021, Veiga, 2021284%6,254moderatelow deaths (time to event analysis only)detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47] CP-COVID-19, 2021 3.20 [0.62; 16.39] REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93] Talaschian, 2021 1.25 [0.30; 5.14] 0.89[0.66; 1.20]COALITION II Covid-19 Brazil (Furtado), 2020, CP-COVID-19, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, Talaschian, 2021547%1,588moderatenot evaluable clinical deteriorationdetailed resultsCAPSID, 2021 0.63 [0.29; 1.40] CODEX (Tomazini), 2020 0.66 [0.43; 1.02] CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20] Shu, 2020 0.27 [0.01; 5.58] 0.63[0.45; 0.88]CAPSID, 2021, CODEX (Tomazini), 2020, CORIMUNO-TOCI-1 (Group 1), 2020, Shu, 202040%575moderatenot evaluable clinical improvementdetailed resultsCao, 2020 1.31 [0.94; 1.83] CAPSID, 2021 1.58 [0.71; 3.49] COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07] Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12] Li, 2020 1.40 [0.79; 2.49] Pouladzadeh, 2021 7.31 [1.62; 32.97] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06] REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15] Sekine (PLACOVID), 2021 0.94 [0.74; 1.19] Shu, 2020 10.27 [1.17; 90.18] 1.29[0.95; 1.75]Cao, 2020, CAPSID, 2021, COALITION II Covid-19 Brazil (Furtado), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Li, 2020, Pouladzadeh, 2021, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (tocilizumab), 2021, Sekine (PLACOVID), 2021, Shu, 20201074%2,067moderatelow clinical improvement (14-day)detailed resultsCao, 2020 1.94 [1.09; 3.48] COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07] Li, 2020 2.27 [0.90; 5.72] REMAP-CAP (lopinavir/ritonavir only), 2020 0.85 [0.64; 1.12] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06] Shu, 2020 10.27 [1.17; 90.18] 1.11[0.72; 1.70]Cao, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, Li, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, Shu, 2020673%1,791moderateserious clinical improvement (28-day)detailed resultsAbuhasira, 2021 1.70 [0.52; 5.49] Cao, 2020 1.59 [0.84; 3.03] COALITION II Covid-19 Brazil (Furtado), 2020 0.70 [0.47; 1.04] Li, 2020 1.42 [0.65; 3.10] Pouladzadeh, 2021 7.31 [1.62; 32.97] Sekine (PLACOVID), 2021 0.94 [0.74; 1.19] Shu, 2020 3.68 [0.18; 75.54] 1.23[0.83; 1.82]Abuhasira, 2021, Cao, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, Li, 2020, Pouladzadeh, 2021, Sekine (PLACOVID), 2021, Shu, 2020758%1,024moderateserious clinical improvement (7-day)detailed resultsCao, 2020 3.16 [0.62; 16.06] COALITION II Covid-19 Brazil (Furtado), 2020 0.94 [0.63; 1.40] Li, 2020 0.98 [0.27; 3.58] Shu, 2020 6.72 [1.50; 30.07] 1.74[0.70; 4.33]Cao, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, Li, 2020, Shu, 2020462%740moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsAbuhasira, 2021 1.22 [0.70; 2.14] Cao, 2020 1.31 [0.94; 1.83] Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12] Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18] Li, 2020 1.40 [0.79; 2.49] Rahmani, 2020 3.41 [1.33; 8.73] 1.48[1.16; 1.89]Abuhasira, 2021, Cao, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Li, 2020, Rahmani, 202068%313moderatenot evaluable death or ventilationdetailed resultsCORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31] Veiga, 2021 1.54 [0.65; 3.63] 0.93[0.35; 2.49]CORIMUNO-TOCI-1 (Group 1), 2020, Veiga, 2021263%260moderatenot evaluable hospital dischargedetailed resultsRahmani, 2020 3.44 [0.64; 18.49] REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.69; 1.00] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.43; 0.92] 0.80[0.55; 1.16]Rahmani, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020356%1,117moderatenot evaluable mechanical ventilationdetailed resultsAbuhasira, 2021 1.62 [0.41; 6.39] AlQahtani, 2020 0.67 [0.22; 2.02] Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67] Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67] Jamaati, 2021 1.38 [0.45; 4.20] Rahmani, 2020 0.29 [0.05; 1.56] Shu, 2020 0.59 [0.02; 14.04] Tabarsi, 2020 1.49 [0.59; 3.78] 1.03[0.66; 1.62]Abuhasira, 2021, AlQahtani, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Jamaati, 2021, Rahmani, 2020, Shu, 2020, Tabarsi, 202080%425moderatenot evaluable mechanical ventilation (time to event analysis only)detailed resultsCP-COVID-19, 2021 0.66 [0.25; 1.72] 0.66[0.25; 1.72]CP-COVID-19, 202110%100NAnot evaluable radiologic improvement (14-day)detailed resultsJamaati, 2021 4.89 [1.15; 20.79] Tabarsi, 2020 2.33 [0.45; 12.00] 3.53[1.19; 10.46]Jamaati, 2021, Tabarsi, 202020%134moderatenot evaluable viral clearance detailed resultsCP-COVID-19, 2021 1.12 [0.16; 7.84] Raman, 2021 36.42 [10.85; 122.18] 6.97[0.23; 210.35]CP-COVID-19, 2021, Raman, 2021289%200moderatenot evaluable viral clearance by day 14detailed resultsCP-COVID-19, 2021 1.51 [0.33; 6.94] Raman, 2021 36.42 [10.85; 122.18] 7.68[0.34; 173.70]CP-COVID-19, 2021, Raman, 2021290%200moderatenot evaluable ICU admissiondetailed resultsAbuhasira, 2021 1.96 [0.51; 7.52] CP-COVID-19, 2021 0.82 [0.35; 1.91] Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71] Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94] Rahmani, 2020 0.37 [0.14; 1.00] Tabarsi, 2020 0.56 [0.18; 1.74] 0.69[0.43; 1.10]Abuhasira, 2021, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Rahmani, 2020, Tabarsi, 202060%394moderatenot evaluable recoverydetailed resultsTalaschian, 2021 0.64 [0.14; 2.92] 0.64[0.14; 2.92]Talaschian, 202110%36NAnot evaluable related SAE (TRSAE)detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 1.24 [0.50; 3.11] 1.24[0.50; 3.11]COALITION II Covid-19 Brazil (Furtado), 202010%439NAnot evaluable serious adverse eventsdetailed resultsCao, 2020 0.52 [0.27; 1.01] COALITION II Covid-19 Brazil (Furtado), 2020 1.20 [0.82; 1.77] CODEX (Tomazini), 2020 0.53 [0.17; 1.62] Raman, 2021 0.49 [0.02; 15.10] REMAP-CAP (lopinavir/ritonavir only), 2020 1.57 [0.70; 3.49] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.97 [0.22; 4.33] REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46] Sekine (PLACOVID), 2021 1.14 [0.88; 1.48] Talaschian, 2021 7.93 [0.37; 171.38] Veiga, 2021 1.66 [0.60; 4.59] 1.16[0.86; 1.55]Cao, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, CODEX (Tomazini), 2020, Raman, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (plasma), 2021, Sekine (PLACOVID), 2021, Talaschian, 2021, Veiga, 20211037%4,343moderatelow superinfectiondetailed resultsRahmani, 2020 0.18 [0.02; 1.59] 0.18[0.02; 1.59]Rahmani, 202010%66NAnot evaluable adverse eventsdetailed resultsRaman, 2021 1.36 [0.56; 3.30] Sekine (PLACOVID), 2021 1.08 [0.85; 1.38] Shu, 2020 2.48 [0.05; 132.54] Veiga, 2021 1.65 [0.81; 3.37] 1.14[0.92; 1.43]Raman, 2021, Sekine (PLACOVID), 2021, Shu, 2020, Veiga, 202140%430moderatenot evaluable long QTdetailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 0.90 [0.56; 1.43] 0.90[0.56; 1.43]COALITION II Covid-19 Brazil (Furtado), 202010%439NAnot evaluable renal impairmentdetailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 1.44 [0.99; 2.11] 1.44[0.99; 2.11]COALITION II Covid-19 Brazil (Furtado), 202010%439NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-05-08 07:00 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290